By binding to PD-L1, PDLpfeRNAa enhances the PD-1/PD-L1 interaction, while PDLpfRNAb inhibits it, favoring or inhibiting, respectively, tumor immune escape [16,17]. Here, CD274 is linked to neoplasm.